GGrantIndex
← Leaderboards

Gary Arthur Silverman

Children'S Hospital Boston

$22,624,651
Attributed
$23,480,370
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,480,370 · 12

By mechanism

R01$10,387,191 · 7
T32$5,270,090 · 2
K12$4,443,574 · 1
P01$3,379,515 · 2

Top collaborators

Most similar at Children'S Hospital Boston

Same institution · by research overlap

Others in their field

Top investigators on “Pathway Interactions

Research focus

Pathway InteractionsCaenorhabditis ElegansChildhoodGeneticBasePlayAnimalsInjuryProtease InhibitorCellsRna InterferencePhenotypeMutantTissuesAffinity ChromatographyUniversitiesGenetic ScreeningLibrariesLiver DiseasesEndoplasmic ReticulumDrug DiscoveryMolecularAffectGrowth

Grant awards (63)

Child Health Research Center$459,000
K12 · FY2025 · HD · contact PI
Training of the Pediatric Physician-Scientist$378,330
T32 · FY2025 · HD · contact PI
Child Health Research Center$459,000
K12 · FY2024 · HD · contact PI
Training of the Pediatric Physician-Scientist$327,854
T32 · FY2024 · HD · contact PI
Child Health Research Center$444,469
K12 · FY2023 · HD · contact PI
Drug Therapies Identified through Modeling AT Deficiency in C Elegans$397,080
P01 · FY2023 · DK · contact PI
Training of the Pediatric Physician-Scientist$316,270
T32 · FY2023 · HD · contact PI
Child Health Research Center$425,208
K12 · FY2022 · HD · contact PI
Drug Therapies Identified through Modeling AT Deficiency in C Elegans$403,484
P01 · FY2022 · DK · contact PI
Training of the Pediatric Physician-Scientist$300,167
T32 · FY2022 · HD · contact PI
Child Health Research Center$452,495
K12 · FY2021 · HD · contact PI
Inhibitors of Intestinal Epithelial Cell Lysosomal-Mediated Necrosis$419,024
R01 · FY2021 · DK · contact PI
Drug Therapies Identified through Modeling AT Deficiency in C Elegans$412,864
P01 · FY2021 · DK · contact PI
Training of the Pediatric Physician-Scientist$317,814
T32 · FY2021 · HD · contact PI
Child Health Research Center$459,000
K12 · FY2020 · HD · contact PI
Inhibitors of Intestinal Epithelial Cell Lysosomal-Mediated Necrosis$419,024
R01 · FY2020 · DK · contact PI
Drug Therapies Identified through Modeling AT Deficiency in C Elegans$418,366
P01 · FY2020 · DK · contact PI
Training of the Pediatric Physician-Scientist$308,071
T32 · FY2020 · HD · contact PI
Drug Therapies Identified through Modeling AT Deficiency in C Elegans$436,500
P01 · FY2019 · DK · contact PI
Child Health Research Center$427,471
K12 · FY2019 · HD · contact PI
Inhibitors of Intestinal Epithelial Cell Lysosomal-Mediated Necrosis$419,024
R01 · FY2019 · DK · contact PI
Genetic Modifiers Affecting Cellular Injury in Alpha-1-Antitrypsin Deficiency$343,125
R01 · FY2019 · DK · contact PI
Training of the Pediatric Physician-Scientist$303,440
T32 · FY2019 · HD · contact PI
Inhibitors of Intestinal Epithelial Cell Lysosomal-Mediated Necrosis$454,366
R01 · FY2018 · DK · contact PI
Child Health Research Center$452,931
K12 · FY2018 · HD · contact PI
Genetic Modifiers Affecting Cellular Injury in Alpha-1-Antitrypsin Deficiency$343,125
R01 · FY2018 · DK · contact PI
Training of the Pediatric Physician-Scientist$304,843
T32 · FY2018 · HD · contact PI
Child Health Research Center$432,000
K12 · FY2017 · HD · contact PI
Genetic Modifiers Affecting Cellular Injury in Alpha-1-Antitrypsin Deficiency$343,125
R01 · FY2017 · DK · contact PI
Training of the Pediatric Physician-Scientist$238,276
T32 · FY2017 · HD · contact PI
Child Health Research Center$432,000
K12 · FY2016 · HD · contact PI
Genetic Modifiers Affecting Cellular Injury in Alpha-1-Antitrypsin Deficiency$343,125
R01 · FY2016 · DK · contact PI
Training of the Pediatric Physician-Scientist$282,732
T32 · FY2016 · HD · contact PI
Drug therapies identified through modeling AT deficiency in C. elegans$343,934
P01 · FY2015 · DK · contact PI
Drug therapies identified through modeling AT deficiency in C. elegans$350,944
P01 · FY2014 · DK · contact PI
Drug therapies identified through modeling AT deficiency in C. elegans$345,764
P01 · FY2013 · DK · contact PI
Intracellular Serpin Regulation of Intestinal Cell Necrosis$384,895
R01 · FY2012 · DK · contact PI
Drug therapies identified through modeling AT deficiency in C. elegans$270,579
P01 · FY2012 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$546,349
R01 · FY2011 · DK · contact PI
Intracellular Serpin Regulation of Intestinal Cell Necrosis$396,441
R01 · FY2011 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$557,302
R01 · FY2010 · DK · contact PI
Intracellular Serpin Regulation of Intestinal Cell Necrosis$412,459
R01 · FY2010 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$92,001
R01 · FY2010 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$552,854
R01 · FY2009 · DK · contact PI
Intracellular Serpin Regulation of Intestinal Cell Necrosis$416,625
R01 · FY2009 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$80,234
R01 · FY2009 · DK · contact PI
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency$540,159
R01 · FY2008 · DK · contact PI
LIMITING CELLULAR INJURY--THE ROLE OF CYTOSOLIC SERPIN$288,990
R01 · FY2005 · CA
LIMITING CELLULAR INJURY--THE ROLE OF CYTOSOLIC SERPIN$299,417
R01 · FY2004 · CA
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$273,600
R01 · FY2004 · CA
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$5,580
R01 · FY2004 · CA
PATHOBIOLOGY OF NEWBORN AND DEVELOPMENTAL DISEASES$654,774
T32 · FY2003 · HD
LIMITING CELLULAR INJURY--THE ROLE OF CYTOSOLIC SERPIN$299,417
R01 · FY2003 · CA
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$279,180
R01 · FY2003 · CA
PATHOBIOLOGY OF NEWBORN AND DEVELOPMENTAL DISEASES$599,784
T32 · FY2002 · HD
PROTEOGLYCANS AND BASAL LAMINA STRUCTURE/FUNCTION$445,818
R01 · FY2002 · CA
LIMITING CELLULAR INJURY--THE ROLE OF CYTOSOLIC SERPIN$299,417
R01 · FY2002 · CA
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$279,180
R01 · FY2002 · CA
PATHOBIOLOGY OF NEWBORN AND DEVELOPMENTAL DISEASES$442,482
T32 · FY2001 · HD
LIMITING CELLULAR INJURY--THE ROLE OF CYTOSOLIC SERPINS$295,497
R01 · FY2001 · CA
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$279,180
R01 · FY2001 · CA
PATHOBIOLOGY OF NEWBORN AND DEVELOPMENTAL DISEASES$495,253
T32 · FY2000 · HD
BIOCHEMICAL AND BIOLOGICAL ANALYSIS OF THE OV SERPINS$278,658
R01 · FY2000 · CA